Skip to main content
Donate

Industry

News

Oct 8, 2026: Ultragenyx Community Webinar

In September, Ultragenyx announced their phase 3 trial for GTX-102 (Aspire) did not meet primary or key secondary endpoints.

To learn more, join Ultragenyx on a community webinar hosted by ASF and FAST on Thursday, October 8, 2026 at 2:00pm EST. Submit your questions and register below.

Webinar registration: https://bit.ly/UGX-Webinar-Oct-2026

Related

Skylark Bio announces investigational gene therapy in develop for Angelman syndrome.
Ionis Pharmaceuticals: A letter to the Angelman syndrome community.
Oak Hill Bio: A Message to the Angelman Syndrome Community
Ultragenyx Announces Phase 3 Aspire results in Angelman Syndrome

View All News

Disclaimer

This website contains information for a broad audience and may include information on current and upcoming programs that are not yet approved or accessible The information provided is for general informational purposes only and is not intended as medical advice, diagnosis, or treatment. While FAST strives to provide accurate and up-to-date information, the content on this site may not always reflect the most current research or clinical guidelines. The inclusion of clinical trial information, treatments or specific healthcare providers does not imply endorsement, recommendation or guarantee of safety, efficacy, or availability. Reliance on any information provided by this website is solely at your own risk. FAST disclaims any liability for any errors or omissions in the information provided or for any decisions made based on this information. For personalized medical advice or specific health concerns including participation in any clinical trial, please consult a qualified healthcare professional.